Analysts Set Omeros Co. (NASDAQ:OMER) PT at $22.50

Omeros Co. (NASDAQ:OMER) has received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $22.50.

Several equities analysts have recently weighed in on OMER shares. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Thursday, January 16th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Finally, Rodman & Renshaw started coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. MML Investors Services LLC raised its holdings in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. SPC Financial Inc. bought a new position in shares of Omeros during the third quarter valued at about $77,000. SG Americas Securities LLC purchased a new position in Omeros during the third quarter worth about $80,000. Finally, AQR Capital Management LLC bought a new position in shares of Omeros during the 2nd quarter worth approximately $105,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Down 1.9 %

NASDAQ:OMER opened at $9.15 on Friday. The firm has a market capitalization of $530.24 million, a P/E ratio of -3.96 and a beta of 2.01. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The company has a fifty day moving average of $9.45 and a 200-day moving average of $6.07.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.